MicroRNA 9-3p Targets β(1) Integrin To Sensitize Claudin-Low Breast Cancer Cells to MEK Inhibition

Yazar: Zawistowski, Jon S., Nakamura, Kazuhiro, Parker, Joel S., Granger, Deborah A., Golitz, Brian T., Johnson, Gary L.
Baskı/Yayın Bilgisi 2013

SWI/SNF Chromatin-Remodeling Factor Smarcd3/Baf60c Controls Epithelial-Mesenchymal Transition by Inducing Wnt5a Signaling

Yazar: Jordan, Nicole Vincent, Prat, Aleix, Abell, Amy N., Zawistowski, Jon S., Sciaky, Noah, Karginova, Olga A., Zhou, Bingying, Golitz, Brian T., Perou, Charles M., Johnson, Gary L.
Baskı/Yayın Bilgisi 2013

PARC/CUL9 Mediates the Degradation of Mitochondrial-released Cytochrome c and Promotes Survival in Neurons and Cancer Cells

Yazar: Gama, Vivian, Swahari, Vijay, Schafer, Johanna, Kole, Adam J., Evans, Allyson, Huang, Yolanda, Cliffe, Anna, Golitz, Brian, Sciaky, Noah, Pei, Xin-Hai, Xiong, Yue, Deshmukh, Mohanish
Baskı/Yayın Bilgisi 2014

GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer.

Yazar: Bevill, Samantha M., Olivares-Quintero, Jose F., Sciaky, Noah, Golitz, Brian T., Singh, Darshan, Beltran, Adriana S., Rashid, Naim U., Stuhlmiller, Timothy J., Hale, Andrew, Moorman, Nathaniel J., Santos, Charlene M., Angus, Steven P., Zawistowski, Jon S., Johnson, Gary L.
Yayımlandı Mol Cancer Res (2019)

TMIC-25. DISSECTING THE ROLE OF HOST GENETICS IN GLIOMA EVOLUTION USING GENETICALLY-ENGINEERED MOUSE MODELS AND THE COLLABORATIVE CROSS

Yazar: Skinner, Kasey, Ferris, Martin, Bash, Ryan, Shelton, Abigail, Smithberger, Erin, Angus, Steven, Golitz, Brian, Sciacky, Noah, Simon, Jeremy, Stein, Jason, Matsushima, Glenn, Ostrom, Quinn, Stetson, Lindsay, Barnholtz-Sloan, Jill, Dhruv, Harshil, Berens, Michael, de Villena, Fernando Pardo Manuel, Miller, Ryan
Yayımlandı Neuro Oncol (2018)

Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy

Yazar: Lipner, Matthew B., Peng, Xianlu L., Jin, Chong, Xu, Yi, Gao, Yanzhe, East, Michael P., Rashid, Naim U., Moffitt, Richard A., Herrera Loeza, Silvia G., Morrison, Ashley B., Golitz, Brian T., Vaziri, Cyrus, Graves, Lee M., Johnson, Gary L., Yeh, Jen Jen
Yayımlandı JCI Insight (2020)

Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer

Yazar: Van Swearingen, Amanda E D, Sambade, Maria J, Siegel, Marni B, Sud, Shivani, McNeill, Robert S, Bevill, Samantha M, Chen, Xin, Bash, Ryan E, Mounsey, Louisa, Golitz, Brian T, Santos, Charlene, Deal, Allison, Parker, Joel S, Rashid, Naim, Miller, C Ryan, Johnson, Gary L, Anders, Carey K
Yayımlandı Neuro Oncol (2017)

Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth

Yazar: Krulikas, Linas J., McDonald, Ian M., Lee, Benjamin, Okumu, Denis O., East, Michael P., Gilbert, Thomas S. K., Herring, Laura E., Golitz, Brian T., Wells, Carrow I., Axtman, Allison D., Zuercher, William J., Willson, Timothy M., Kireev, Dmitri, Yeh, Jen Jen, Johnson, Gary L., Baines, Antonio T., Graves, Lee M.
Yayımlandı SLAS Discov (2018)

Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex

Yazar: Zawistowski, Jon S., Bevill, Samantha M., Goulet, Daniel R., Stuhlmiller, Timothy J., Beltran, Adriana S., Olivares-Quintero, Jose F., Singh, Darshan, Sciaky, Noah, Parker, Joel S., Rashid, Naim U., Chen, Xin, Duncan, James S., Whittle, Martin C., Angus, Steven P., Velarde, Sara Hanna, Golitz, Brian T., He, Xiaping, Santos, Charlene, Darr, David B., Gallagher, Kristalyn, Graves, Lee M., Perou, Charles M., Carey, Lisa A., Earp, H. Shelton, Johnson, Gary L.
Yayımlandı Cancer Discov (2017)